A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Acronyms ASTEROID 1
- Sponsors Bayer
- 19 Oct 2016 Results presented at the 72nd Annual Meeting of the American Society for Reproductive Medicine
- 13 Oct 2016 Latest clinical data from this trial will be presented at the 72nd American Society of Reproductive Medicine (ASRM) Scientific Congress, as reported by a Bayer media release.
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.